首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal SET Antibody

  • 中文名： SET抗体
  • 别    名： 2PP2A; IGAAD; TAF-I; I2PP2A; IPP2A2; PHAPII; TAF-IBETA
货号: IPDX23062
Price： ￥1180
数量：
大包装询价

验证与应用

应用及物种
WB 1/500-1/1000 Human,Mouse,Rat
IF 1/20 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 1/50-1/200 Human,Mouse,Rat
FCM 1/50-1/100 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

Aliases2PP2A; IGAAD; TAF-I; I2PP2A; IPP2A2; PHAPII; TAF-IBETA
Entrez GeneID6418
WB Predicted band sizeCalculated MW: 33 kDa; Observed MW: 39 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthesized peptide derived from human SET
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

参考文献

以下是关于SET抗体的3篇代表性文献的简要信息(基于公开研究总结，非真实引用，仅供示例参考)：

1. **文献名称**：*The oncoprotein SET as a biomarker: structural insights and antibody development*

**作者**：Smith A, et al.

**摘要**：该研究解析了SET蛋白的晶体结构，揭示了其抑制PP2A磷酸酶活性的分子机制，并开发了高特异性单克隆抗体用于癌症组织检测，为肿瘤预后评估提供了工具。

2. **文献名称**：*SET overexpression promotes tumor immune evasion via histone modification*

**作者**：Li X, et al.

**摘要**：研究发现SET蛋白通过组蛋白甲基化修饰抑制干扰素通路相关基因表达，导致肿瘤免疫逃逸。文中利用SET抗体验证了其在黑色素瘤模型中的表达与T细胞浸润负相关。

3. **文献名称**：*Targeting SET-PP2A interaction as a therapeutic strategy in Alzheimer's disease*

**作者**：Wang Y, et al.

**摘要**：通过SET抗体阻断实验，证实抑制SET与PP2A的结合可恢复tau蛋白去磷酸化，减少神经纤维缠结，为阿尔茨海默病提供了潜在治疗靶点。

---

**注**：以上为模拟示例，实际文献需通过PubMed/Google Scholar检索关键词如“SET antibody”、“SET protein function”等获取。真实研究可参考：

- SET复合物与表观遗传调控(如 *Nature Cell Biology* 相关论文)

- SET在白血病中的致癌机制(如 *Blood* 期刊研究)

- SET抗体在临床诊断中的应用(如 *Clinical Cancer Research* 文献)

背景信息

SET antibodies target the SET protein, a multifunctional nuclear protein implicated in chromatin remodeling, gene regulation, and DNA repair. Originally identified as an inhibitor of Protein Phosphatase 2A (PP2A), SET (also known as I2PP2A or TAF-I) consists of two conserved domains: the N-terminal region binds histones to modulate chromatin structure, while the C-terminal domain suppresses PP2A activity, disrupting cellular signaling pathways. Dysregulation of SET is linked to cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, SET overexpression promotes tumorigenesis by enhancing cell proliferation, metastasis, and chemoresistance via PP2A inhibition and epigenetic alterations. In Alzheimer’s disease, SET accumulates in neuronal tangles, potentially exacerbating tau hyperphosphorylation. Autoantibodies against SET are observed in systemic lupus erythematosus, suggesting its role in autoimmune pathogenesis. Research on SET antibodies focuses on their utility in detecting SET expression patterns, subcellular localization, and protein interactions in disease models. Therapeutic strategies aim to inhibit SET’s oncogenic functions using small-molecule inhibitors or peptide-based agents, some in preclinical or early clinical trials. These efforts highlight SET’s dual role as both a biomarker and a therapeutic target in diverse pathologies.

客户数据及评论

折叠内容

大包装询价

×